Please use this identifier to cite or link to this item:
|Title:||Waiver Solution in Public Health and Pharmaceutical Domain under TRIPS Agreement|
|Abstract:||WTO adopted the waiver solution in compulsory licensing, beginning from the Doha Declaration to the amendment of TRIPS Agreement, to facilitate access to medicine to the countries lacking manufacturing capacity. This article examines challenges faced by countries while issuing compulsory licensing; waiver decision with regard to Article 31(f) and 31 (h) of TRIPS Agreement. The article further analyses the causes as to why the waiver solution has not been as effective as it was hoped and envisages an increase in its importance in the coming days.|
|ISSN:||0975-1076 (Online); 0971-7544 (Print)|
|Appears in Collections:||JIPR Vol.16(6) [November 2011]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.